Mifegyne

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a tablet for oral use. It treats medical termination of intrauterine pregnancy, cervical ripening before surgical abortion, and management of early pregnancy loss in women. GNH USA supplies Mifegyne as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifegyne is a progesterone receptor antagonist used in early pregnancy management. - Medical termination of intrauterine pregnancy: induces abortion in early gestation under medical supervision. - Cervical ripening prior to surgical abortion: softens the cervix to facilitate operative procedures. - Management of early pregnancy loss: assists in expelling retained products of conception.

Mifegyne may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vaginal bleeding: variable intensity, often heavier than a normal period. - Cramping: uterine pain associated with tissue expulsion. - Fatigue: general tiredness during the process.

Serious or Rare Side Effects: - Severe infection: signs include fever, foul discharge, or abdominal pain. - Heavy hemorrhage: excessive blood loss requiring medical attention. - Allergic reaction: rash, itching, swelling, or difficulty breathing.

Mifegyne requires careful patient assessment and monitoring. - Confirm gestational age: ensure pregnancy is within approved limits (typically ≤10 weeks). - Exclude ectopic pregnancy: rule out non‑uterine implantation before use. - Assess contraindications: avoid in patients with chronic adrenal failure or long‑term corticosteroid therapy. - Provide follow‑up: schedule post‑treatment evaluation to confirm complete abortion. - Store at ambient temperature: keep below 25°C, in original packaging, protected from moisture and light.

Mifegyne can interact with other medicines that affect its metabolism or uterine activity.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce mifepristone effectiveness. - Antifungal azoles (e.g., ketoconazole): may increase plasma concentrations, raising risk of adverse effects.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding risk. - NSAIDs: may increase uterine cramping. - Hormonal contraceptives: may be less effective during treatment.